New Clinical Development Program in Osteosarcoma

This past Sunday at the Sarcoma Foundation of America’s Annual Patient Educational Conference, attendees heard a very interesting presentation from Dr. Nicola Mason regarding research for a promising new therapy for osteosarcoma in canines. It was particularly exciting to learn from Dr. Mason that the preliminary data from this study shows a strong rationale to begin exploring this potential therapy in humans.  A day later, Advaxis, the biotechnology company developing this potential therapy, announced in a press release that it “intends to initiate a clinical development program with its product candidate, ADXS-cHER2, for the treatment of pediatric osteosarcoma.” To give…  Read More »